



EXPRESS MAIL NO. EV335611037US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : William L. Hunter et al.
Application No. : 10/671,327
Filed : September 25, 2003
For : COMPOSITIONS AND METHODS FOR TREATING OR
PREVENTING DISEASES OF BODY PASSAGEWAYS

Art Unit : 1617
Examiner : Edward J. Webman
Docket No. : 110129.405C3
Date : October 19, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Supplemental Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Qing Lin, Ph.D.
Registration No. 53,937

QXL:ljt

Enclosures:

Form PTO-1449

Cited References (X 2)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

\525168

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
110129.405C3APPLICATION NO.
10/671,327**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

William L. Hunter et al.

FILING DATE

September 25, 2003

GROUP ART UNIT

1617

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
	AK				
	AL				
	AM				
	AN				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AO	Geary, R.L. et al., "Failure of Heparin to Inhibit Intimal Hyperplasia in Injured Baboon Arteries," <i>Circulation</i> 91: 1-19, http://circ.ahajournals.org/cgi/content/full/91/12/2972 , retrieved October 18, 2004.
AP	Muller, D.W.M. et al., "Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation," <i>Coronary Artery Disease</i> 5: 435-442, 1994.
AQ	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).